APRE — Aprea Therapeutics, Inc.

Is APRE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Aprea Therapeutics, Inc. (APRE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.69. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Aprea Therapeutics is a small clinical-stage biotech whose valuation is primarily driven by the outcomes of a limited number of programs and its ability to fund development. The current market tone is risk-off, which increases near-term funding and M&A headwinds for speculative healthcare names. Key positives include meaningful upside from favorable trial readouts or strategic partnerships; negatives include high dilution risk, binary clinical outcomes, regulatory uncertainty, and competitive pressure. Absent a near-term positive catalyst or clear financing solution, the stock is likely to remain volatile and sensitive to trial news and broader market risk sentiment.

Key factors

  • Clinical-stage pipeline: company value is highly dependent on timing and outcome of upcoming clinical readouts; positive data could be material upside.
  • Cash runway and financing needs: small-cap biotech with limited revenue; likely need for additional capital or partnerships within 12–18 months.
  • Concentration risk: few assets and limited commercial diversity increases binary outcome exposure to single-trial results.
  • Market environment: current risk-off tone and cooling healthcare IPO/venture activity reduce near-term funding and M&A appetite for speculative names.
  • Potential for partnership/licensing: strategic collaborations or buyouts could de-risk balance sheet and accelerate development, representing a key upside catalyst.
  • Regulatory and reimbursement landscape: evolving payer scrutiny (including Medicare negotiation dynamics) could affect future pricing and commercial access for novel therapies.

Risks

  • Negative or inconclusive clinical trial results leading to sharp share price declines.
  • Dilution risk from near-term financing if cash runway is insufficient for planned programs.
  • Regulatory delays or requests for additional data that push timelines and increase costs.
  • Commercial/reimbursement pressure from policy actions and payer negotiation reducing expected pricing power.
  • Competitive advances from larger biopharma (including combination therapies) that crowd the addressable market.
  • Low liquidity and thin trading volume amplifying volatility and limiting exit options for holders.

See today's live rating, score and targets

Members see the live hourly rating for APRE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.